Neurogene Capital Lease Obligations vs Total Stockholder Equity Analysis
| NGNE Stock | 22.50 0.14 0.62% |
Neurogene financial indicator trend analysis is infinitely more than just investigating Neurogene recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurogene is a good investment. Please check the relationship between Neurogene Capital Lease Obligations and its Total Stockholder Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.
Capital Lease Obligations vs Total Stockholder Equity
Capital Lease Obligations vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurogene Capital Lease Obligations account and Total Stockholder Equity. At this time, the significance of the direction appears to have weak relationship.
The correlation between Neurogene's Capital Lease Obligations and Total Stockholder Equity is 0.32. Overlapping area represents the amount of variation of Capital Lease Obligations that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Neurogene, assuming nothing else is changed. The correlation between historical values of Neurogene's Capital Lease Obligations and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Lease Obligations of Neurogene are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Capital Lease Obligations i.e., Neurogene's Capital Lease Obligations and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.32 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Capital Lease Obligations
Neurogene capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Neurogene asset purchases. For example, Neurogene can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Neurogene control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Neurogene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurogene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.As of December 24, 2024, Selling General Administrative is expected to decline to about 10.4 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 76.8 M
| 2022 | 2023 | 2024 (projected) | Net Interest Income | 1.3M | 2.9M | 1.6M | Cost Of Revenue | 3.2M | 3.3M | 2.4M |
Neurogene fundamental ratios Correlations
Click cells to compare fundamentals
Neurogene Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neurogene fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 147.0M | 210.5M | 101.5M | 109.3M | 222.6M | 155.8M | |
| Short Long Term Debt Total | 1.2M | 12.1M | 5.2M | 4.7M | 16.3M | 17.1M | |
| Other Current Liab | 2.5M | 5.9M | 4.6M | 5.3M | 17.5M | 18.4M | |
| Total Current Liabilities | 4.7M | 7.9M | 10.9M | 6.7M | 23.0M | 24.1M | |
| Total Stockholder Equity | 141.7M | 191.2M | (91.9M) | (145.7M) | 186.0M | 195.3M | |
| Property Plant And Equipment Net | 2.8M | 13.7M | 27.5M | 24.5M | 21.0M | 12.6M | |
| Net Debt | (141.9M) | (180.4M) | (65.3M) | (77.3M) | (132.0M) | (138.6M) | |
| Retained Earnings | (299.5M) | (332.8M) | (95.6M) | (150.8M) | (187.2M) | (196.5M) | |
| Cash | 143.1M | 192.6M | 70.5M | 82.0M | 148.2M | 109.7M | |
| Non Current Assets Total | 3.4M | 16.0M | 27.5M | 24.5M | 22.2M | 20.2M | |
| Non Currrent Assets Other | 597.0K | 2.3M | (878K) | 87K | 764K | 480.6K | |
| Cash And Short Term Investments | 143.1M | 192.6M | 70.5M | 82.0M | 197.2M | 133.8M | |
| Common Stock Shares Outstanding | 27.0M | 51.8M | 55.0M | 12.8M | 14.7M | 14.0M | |
| Liabilities And Stockholders Equity | 147.0M | 210.5M | 101.5M | 109.3M | 222.6M | 155.8M | |
| Non Current Liabilities Total | 593K | 11.4M | 182.5M | 248.4M | 13.6M | 12.9M | |
| Other Current Assets | 503K | 2.0M | 3.4M | 1.7M | 2.6M | 1.6M | |
| Other Stockholder Equity | 441.2M | 524.0M | 3.8M | 5.1M | 373.2M | 224.1M | |
| Total Liab | 5.3M | 19.3M | 193.4M | 255.0M | 36.5M | 34.7M | |
| Total Current Assets | 143.6M | 194.5M | 74.0M | 84.7M | 200.3M | 135.7M | |
| Accounts Payable | 1.6M | 1.3M | 5.6M | 625K | 2.6M | 2.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.66) | Revenue Per Share 0.106 | Return On Assets (0.32) | Return On Equity (0.41) |
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.